Cover Image

Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis

Purpose: TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis.Design: Randomized, prospective, controlled, two-center clinical trialMethods: Patients with active uv...

Full description

Saved in:
Bibliographic Details
Main Authors: Mackensen, Friederike (Author) , Jakob, Eva (Author) , Grewing, Viviane (Author) , Lorenz, Hanns-Martin (Author) , Max, Regina (Author) , Becker, Matthias D. (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: Ocular immunology and inflammation
Year: 2017, Volume: 26, Issue: 7, Pages: 1015-1022
ISSN:1744-5078
DOI:10.1080/09273948.2017.1411518
Online Access:Verlag, Volltext: http://dx.doi.org/10.1080/09273948.2017.1411518
Verlag, Volltext: https://doi.org/10.1080/09273948.2017.1411518
Get full text
Author Notes:Friederike Mackensen, MD, Carsten Heinz, MD, Eva Jakob, MD, Viviane Grewing, MD, Hanns-Martin Lorenz, MD, Arnd Heiligenhaus, MD, Regina Max, MD, and Matthias D. Becker, MD, PhD
Description
Summary:Purpose: TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis.Design: Randomized, prospective, controlled, two-center clinical trialMethods: Patients with active uveitis despite combined oral low-dose prednisolone and immunosuppression were randomized for additional ADA with corticosteroids in a fixed tapering regime, or corticosteroids only. Primary outcome measure at three months was improved best-corrected visual acuity (BCVA; >2 lines). In case of treatment failure, switch to the other arm was possible.Results: Twenty-five patients (10 ADA, 15 controls) were included. BCVA increased with ADA by > 2 lines in 6/10 patients (60%; mean increase of 0.23 logMAR), but in only 2/15 from controls (13%, mean increase of 0.04 logMAR, Fisher´s exact test p = 0.00221).Conclusions: The results show superiority of ADA over controls in severe ocular inflammation including anterior uveitis.
Item Description:Published online: 29 Dec 2017
Gesehen am 05.08.2019
Physical Description:Online Resource
ISSN:1744-5078
DOI:10.1080/09273948.2017.1411518

Similar Items